Aspergillus Updates week 51
1. Immunodeficiency, rare syndromes & aspergillosis risk
Standing Still: A Case of Stiff Person Syndrome and Common Variable Immunodeficiency
Khazar et al., Cureus, 2025
Summary
-
Describes a rare coexistence of Stiff Person Syndrome (SPS) and Common Variable Immunodeficiency (CVID).
-
Highlights autoimmune–immunodeficiency overlap and diagnostic complexity.
Why it matters
-
CVID is a recognised risk factor for recurrent infections and chronic lung disease, including bronchiectasis and chronic pulmonary aspergillosis (CPA).
-
Reinforces the need for multisystem thinking when patients present with neurological and respiratory symptoms.
Limitations
-
Single case; no fungal infection reported.
-
Indirect relevance to aspergillosis but important for risk stratification.
Beyond Cystic Fibrosis: Recognising Shwachman–Diamond Syndrome in the Respiratory Clinic
Yang et al., Respirology Case Reports, 2025
Summary
-
Emphasises misdiagnosis of Shwachman–Diamond syndrome (SDS) as cystic fibrosis.
-
Includes discussion of allergic bronchopulmonary aspergillosis (ABPA) in the differential.
Why it matters
-
Reinforces that non-CF genetic syndromes can present with:
-
Bronchiectasis
-
Recurrent infection
-
ABPA-like features
-
-
Highly relevant to adult respiratory clinics and late diagnoses.
Clinical takeaway
-
ABPA should prompt consideration of underlying immune or genetic disease, not just asthma or CF.
2. Genetics & structural lung disease
Exome sequencing reanalysis identifies a novel CFAP54 variant in primary ciliary dyskinesia
Li et al., Frontiers in Medicine, 2025
Summary
-
Identifies a new likely pathogenic CFAP54 variant.
-
Expands the phenotypic spectrum of Primary Ciliary Dyskinesia (PCD).
Relevance to aspergillosis
-
PCD → impaired mucociliary clearance → chronic infection, bronchiectasis, and secondary fungal disease.
-
ABPA and CPA are increasingly recognised in non-CF bronchiectasis populations.
Strength
-
Genotype–phenotype correlation strengthens diagnostic confidence.
Limitation
-
Aspergillosis not a primary focus, but highly relevant to long-term respiratory outcomes.
3. Haematology, malignancy & invasive aspergillosis
Mixed-Phenotype Acute Leukemia Transforming into AML-M4
Alhayek et al., Cureus, 2025
Summary
-
Case of evolving leukemia complicated by pancytopenia, invasive pulmonary aspergillosis (IPA), and COVID-19.
Key points
-
Illustrates real-world stacked risk:
-
Neutropenia
-
Chemotherapy
-
Viral infection
-
IPA
-
Clinical relevance
-
Strong reminder that IPA often emerges during diagnostic or therapeutic transitions, not just during induction chemotherapy.
Invasive fungal infections in haematologic diseases: evidence, challenges, and practice
Cho et al., Blood Research, 2025 – Review
Summary
-
Comprehensive overview of invasive aspergillosis, candidiasis, and mucormycosis.
-
Covers diagnostics, antifungal resistance, and treatment strategies.
Strengths
-
Practical, guideline-aligned.
-
Emphasises individualised risk assessment and early treatment.
Gap
-
Limited discussion of long-term survivors and post-IPA chronic complications (e.g. CPA).
4. Imaging & diagnostics
CT Pulmonary Angiography in invasive pulmonary aspergillosis
Tian, Future Microbiology, 2025
Summary
-
Explores the role of CT pulmonary angiography (CTPA) in detecting angioinvasion.
Why it matters
-
Vascular occlusion and infarction are hallmarks of IPA.
-
CTPA may improve diagnostic confidence when standard CT is equivocal.
Limitations
-
Case-based evidence.
-
Needs integration into diagnostic algorithms.
Sequential serum galactomannan as an outcome marker
Többen et al., Int J Infect Dis, 2025
Summary
-
Registry-based exploratory analysis of serial galactomannan (GM).
Key finding
-
Trends in GM may correlate with treatment response, not just diagnosis.
Clinical importance
-
Supports GM as a monitoring biomarker, though interpretation remains complex.
Caution
-
Not reliable in all patient groups (e.g. non-neutropenic, antifungal pre-exposure).
5. Chronic pulmonary aspergillosis & structural disease
Molecular epidemiology of Aspergillus species in CPA (South India)
Spruijtenburg et al., Medical Mycology, 2025
Summary
-
Describes species diversity and genetic variation in CPA patients.
Why it matters
-
Highlights:
-
Geographic variation
-
Potential antifungal resistance implications
-
-
Supports species-level identification in CPA.
Strength
-
Strong laboratory–clinical interface.
Advanced pulmonary sarcoidosis
Spagnolo et al., Seminars in Respiratory and Critical Care Medicine, 2025
Summary
-
Reviews complications of advanced sarcoidosis, including:
-
Bronchiectasis
-
Pulmonary hypertension
-
Chronic pulmonary aspergillosis
-
Key point
-
CPA should be actively considered, not viewed as rare, in fibrotic sarcoidosis.
Rezafungin OPAT for chronic pulmonary aspergillosis
Law et al., JAC Antimicrobial Resistance, 2025
Summary
-
First real-world case of rezafungin used via outpatient parenteral therapy for CPA.
-
Includes a health-economic assessment.
Why this is important
-
CPA treatment options are limited.
-
Weekly dosing may:
-
Reduce hospital burden
-
Improve quality of life
-
Caution
-
Single case; echinocandins are not standard CPA therapy.
-
Best viewed as salvage or niche use.
6. Tracheobronchial & atypical aspergillosis
Tracheobronchial Aspergillosis Mimicking Pseudotumour
Castillo Gamboa et al., Clinical Case Reports, 2025
Summary
-
Rare presentation of tracheobronchial aspergillosis masquerading as malignancy.
Clinical lesson
-
Endobronchial disease can be missed or mislabelled.
-
Supports biopsy and fungal testing when appearances are atypical.
7. Immunology, inflammation & host–pathogen interaction
PANoptosis in pathogen infection and systemic disease
Cai et al., Cell Biology and Toxicology, 2025 – Review
Summary
-
Reviews PANoptosis (pyroptosis, apoptosis, necroptosis) in infections.
Relevance
-
Aspergillus is discussed as a trigger of complex inflammatory cell death pathways.
-
May help explain:
-
Severe tissue damage
-
Dysregulated inflammation in IPA
-
Translational value
-
Still mechanistic; clinical applications remain distant.
PD-1 / PD-L1 immune checkpoint in fungal infections
Zheng et al., Virulence, 2025 – Review
Summary
-
Explores immune exhaustion in ABPA, CPA, and IPA.
Key insight
-
Checkpoint pathways may:
-
Contribute to chronic infection persistence
-
Become future adjunctive immunotherapies
-
Important caution
-
Immune checkpoint modulation carries significant risk in fungal disease.
8. Antimicrobial stewardship & prophylaxis
Procalcitonin-guided antibiotics in RSV and influenza
Hessels et al., BMJ Open Respiratory Research, 2025
Finding
-
Reduced antibiotic use without increased fungal infection risk.
Relevance
-
Important reassurance that stewardship does not increase IPA risk in viral respiratory infections.
Letermovir prophylaxis post-HSCT
Kimura et al., J Infect Chemother, 2025
Key result
-
Letermovir did not increase invasive aspergillosis or candidemia risk.
Clinical reassurance
-
Supports ongoing antiviral prophylaxis strategies in transplant patients.
9. Experimental antifungals
Berberine suppresses Aspergillus fumigatus growth
Wang et al., ACS Infectious Diseases, 2025
Summary
-
Demonstrates antifungal activity via:
-
Mitochondrial fragmentation
-
Reactive oxygen species
-
Hog1-MAPK activation
-
-
Reduced fungal burden in a murine IPA model.
Important caution
-
Pre-clinical only.
-
Not a supplement recommendation for patients.
Overall themes & take-home messages
Key trends this week
-
Increasing recognition of rare immunodeficiency and genetic syndromes behind chronic lung disease.
-
Better understanding of non-classical aspergillosis presentations.
-
Strong interest in immune modulation, biomarkers, and novel therapies.
-
Continued need for early diagnosis, especially in haematology and advanced lung disease.
For clinical practice
-
Think beyond labels (asthma, CF, cancer).
-
Revisit diagnoses when disease behaves atypically.
-
CPA and ABPA remain under-recognised but increasingly documented across conditions.
If you’d like, I can:
-
Turn this into a NAC weekly research digest
-
Produce patient-safe summaries of selected papers
-
Extract figures and learning points for teaching or the Knowledge Hub
Aspergillosis Trust – A Community for Patients
The Aspergillosis Trust is a patient-led charity dedicated to helping people affected by aspergillosis and supporting the wider community of patients, carers, families, and friends. It exists to make life with aspergillosis easier by *raising awareness, sharing information, and bringing people together so no one has to go through this alone. *Aspergillosis Trust Charity
Although aspergillosis is a rare condition, the Trust’s vision is simple and powerful: to make aspergillosis widely recognised so it can be diagnosed earlier, treated more effectively, and better understood — by health professionals and the general public alike.
Why the Trust Matters to You
Shared Experience and Support
The Aspergillosis Trust understands what it’s like to live with a rare lung condition because it’s run by patients and carers themselves. This means the insights and support it offers come from real experience, not just medical textbooks. It connects people who have walked similar paths, helping reduce isolation and fostering practical encouragement.
Information You Can Use
The Trust supports people around the world by providing information, resources, and real and virtual support networks. Whether you’re newly diagnosed or navigating long-term treatment, the Trust’s curated links, articles, and connections can help you find reliable answers and understand your options.Charity Commission
Raising Awareness and Understanding
By amplifying patient voices and sharing stories, the Trust helps increase understanding of aspergillosis among doctors, nurses, and healthcare teams. This awareness work helps ensure more people are referred for specialist care sooner, leading to better outcomes.
Where Community Meets Practical Help
-
The Trust offers a network of support and encouragement for people living with aspergillosis.
-
It provides curated links and resources to help you find information relevant to your situation.
-
Through awareness campaigns and shared patient stories, it works to improve understanding and recognition of aspergillosis among clinicians and the public.
Whether you’re looking for knowledge, community, or reassurance that others understand what you’re going through, the Aspergillosis Trust is a valuable companion on your journey.
For more about how to connect or get support, you can visit their website or reach out directly via their contact page.
Why Exposure to Aspergillus (e.g., in a Damp Home) Does Not Usually Mean You Have Aspergillosis
Many people worry that finding mould in a home means they are at serious risk of aspergillosis. This fear is understandable, especially when you have respiratory symptoms. But the truth is:
Exposure to Aspergillus is extremely common, and aspergillosis is rare.
Here’s why most people who encounter Aspergillus never develop disease — and what to look out for if you are at risk.
1. Aspergillus Is Everywhere — Even in Healthy Homes
Aspergillus spores are naturally present in the environment. We breathe them in every day from:
-
Soil, leaves, compost
-
Outdoor air
-
Dust and ventilation systems
-
Older or damp buildings
These spores are so widespread that avoiding them completely is impossible.
The good news is:
For most people, breathing in Aspergillus spores does not cause illness.
The airways and immune system are excellent at clearing them quickly and safely.
2. Damp Homes Increase Exposure — Not Disease
A damp or mouldy home may contain higher levels of spores, but this generally causes:
-
Irritation of the airways
-
Worsening of asthma or allergies
-
Coughing or wheezing
-
Musty smells and reduced air quality
These symptoms can feel unpleasant, but damp housing does not usually cause aspergillosis.
Most health effects of damp homes are related to allergens and irritants, not fungal disease.
3. Aspergillosis Develops Only in Vulnerable People
To develop aspergillosis, a person usually needs underlying risk factors such as:
-
Asthma, bronchiectasis, COPD, or previous TB
-
Weakened immune system
(e.g., due to chemotherapy, high-dose steroids, immunosuppressants) -
A strong allergic tendency (as in Allergic Bronchopulmonary Aspergillosis — ABPA)
Even among these groups, only a minority develop disease.
Exposure alone is not enough.
4. Why Some People Think Exposure “Caused” Their Illness
For people who later develop ABPA or chronic aspergillosis, a first major flare often follows:
-
Living in a damp home
-
Decorating or renovating
-
Gardening or composting
-
Clearing mould or dust
This can give the impression the exposure caused the disease.
In reality:
Exposure usually triggers or reveals an underlying condition — it does not create it.
Underlying immune or lung problems were already present long before the flare.
5. When to Seek Medical Review
See a doctor if you have:
-
A chronic wet cough
-
Mucus plugging
-
Breathlessness that gets worse over months
-
Coughing up blood
-
Repeated chest infections
-
Worsening asthma control
-
Unexplained weight loss
These may indicate ABPA, chronic pulmonary aspergillosis (CPA), or other lung disease.
6. Environmental Improvements Can Still Help
If you have ABPA, CPA, or asthma, improving home conditions can reduce flare-ups:
-
Lower humidity (40–60%)
-
Improve ventilation
-
Repair damp or leaks
-
Use HEPA air filtration
-
Clean or replace old soft furnishings if heavily contaminated
These steps reduce asthma triggers and airway irritation — not because they “remove Aspergillus entirely”, but because they create a healthier breathing environment.
Key Message
Exposure to Aspergillus is normal.
Disease is uncommon and depends on underlying health — not on exposure alone.
Damp homes can trigger symptoms but rarely cause aspergillosis.
Depemokimab – a new long-acting treatment for severe asthma: what aspergillosis patients need to know
A new medicine called depemokimab is being reviewed by European and UK regulators as a possible treatment for severe eosinophilic (type-2) asthma. Many people with aspergillosis-related conditions – especially allergic bronchopulmonary aspergillosis (ABPA) and severe asthma with fungal sensitisation (SAFS) – also have this type of inflammation, so new options are always important.
⭐ What is depemokimab?
Depemokimab is a biologic treatment, similar to medicines like mepolizumab or benralizumab, but designed to last much longer in the body. It blocks interleukin-5 (IL-5), one of the key signals that drives eosinophils – a type of white blood cell involved in allergy, asthma and ABPA flares.
⭐ What makes it different?
The most important difference is how rarely it needs to be taken.
Current biologics for type-2 asthma are given every 4, 6 or 8 weeks.
Depemokimab is designed to be taken twice a year – only once every six months.
For many people, this could mean:
-
Fewer injections
-
More steady asthma control
-
Less disruption to daily life
-
A treatment that’s easier to stick with over time
In clinical trials, depemokimab also helped to:
-
Reduce asthma attacks
-
Lower the need for oral steroids
-
Improve symptoms in people with chronic sinusitis and nasal polyps, which commonly affects ABPA and SAFS patients
⭐ Is this a treatment for ABPA or CPA?
Not specifically.
Depemokimab is not a treatment for the Aspergillus fungus itself and it does not replace antifungal medicines.
However, for people whose asthma drives their ABPA symptoms, better asthma control can mean:
-
fewer flare-ups
-
better breathing
-
less need for steroids
-
reduced pressure on already damaged airways
So while it is not an antifungal, it may become another option in the toolkit for managing asthma linked to aspergillosis.
⭐ When might this be available in the UK?
Depemokimab is currently under review by European regulators.
In the UK, the NICE appraisal for NHS use is underway, with a decision expected in March 2026.
If approved, it could become available on the NHS sometime in 2026.
⭐ What should patients do now?
At this stage:
-
There is no action needed from patients.
-
Your asthma or ABPA team will be the first to know when new biologics are approved.
-
If you already receive a biologic (e.g., mepolizumab, benralizumab, omalizumab, dupilumab), there is no change to your treatment plan.
-
If you struggle with frequent injections or poor asthma control, your clinician may consider depemokimab in the future once approved.
Mycotoxins in Damp Homes: Are They a Hidden Cause of Chronic Illness?
The internet is full of claims that “toxic mould” and “mycotoxins” in damp homes cause chronic fatigue, brain fog, immune disorders, or long-term poisoning.
These stories are frightening — but they are also misleading.
This article explains what mycotoxins are, what risks are real, and why blaming them can delay proper diagnosis and treatment.
1. What Are Mycotoxins?
Mycotoxins are chemicals produced by some fungi. Certain mycotoxins can be harmful — but usually in situations completely different from normal household mould.
Examples include:
-
Aflatoxin in contaminated food crops (mainly in tropical regions)
-
Ochratoxin A in poorly stored grains
-
Trichothecenes from water-damaged materials in rare extreme cases
In UK homes, airborne mycotoxin levels are generally extremely low.
2. Can Mycotoxins in Homes Cause Chronic Illness?
The scientific consensus from WHO, UKHSA, CDC, and NICE is:
No — not at the levels found in typical damp or mouldy houses.
Mycotoxins mainly cause illness by eating contaminated food, not by breathing small amounts in the air.
Symptoms linked to damp homes — fatigue, cough, wheeze, headaches — are usually caused by:
-
Allergens (dust mites, spores)
-
Irritants
-
Cold, damp air
-
Bacteria
-
Volatile organic compounds (VOCs)
-
Poor ventilation
-
Existing asthma or lung disease
These symptoms are real, but they are not mycotoxin poisoning.
3. Why the Myth Persists
Online sources often promote the idea of “mould toxicity” because:
-
It offers a simple explanation for complex symptoms
-
Private companies sell expensive testing kits
-
Influencers share personal stories
-
It feels empowering to “identify” a hidden cause
But most testing marketed as “mycotoxin screening” is not medically valid and often gives false positives.
4. The Real Harm: Misdiagnosis and Delayed Treatment
This is crucial.
People who believe they have “mycotoxin illness” may delay getting proper medical assessment for:
-
ABPA (Allergic Bronchopulmonary Aspergillosis)
-
CPA (Chronic Pulmonary Aspergillosis)
-
SAFS (Severe Asthma with Fungal Sensitisation)
-
Bronchiectasis
-
NTM lung disease
-
Adrenal insufficiency
-
Asthma deterioration
Some conditions worsen without correct treatment, and the delay can be significant.
People may also spend large amounts of money on:
-
Detox supplements
-
“Mould inspections”
-
Repeated home fogging or ozone treatments
-
House moves
-
Throwing away belongings
-
Private “mycotoxin tests”
These rarely help — and often worsen stress and isolation.
5. When Should Someone Be Concerned About Mycotoxins? (Very Rare Cases)
Significant mycotoxin exposure is possible only in:
-
Buildings with severe, long-term water damage
-
Homes where black mould covers large areas and ventilation is extremely poor
-
Certain workplaces (grain stores, composting facilities)
Even then, the main health effects involve irritation and asthma, not systemic poisoning.
6. If You Do Have ABPA, CPA, or Asthma — Home Improvements Can Help
Not because they remove toxins, but because they improve air quality:
-
Lower humidity (40–60%)
-
Fix damp problems
-
Improve ventilation
-
Use HEPA air filters
-
Reduce dust and allergens
-
Clean or replace heavily contaminated soft furnishings
These steps support better respiratory control, particularly in people already living with lung disease.
Key Message
Mycotoxins in UK homes are not a hidden cause of chronic illness.
Believing otherwise can delay diagnosis and treatment of real, treatable conditions such as ABPA, CPA, asthma, and bronchiectasis.
Improving your home environment helps — but it supports lung health, it does not “detox” mycotoxins.
Understanding Aspergillosis Through Imaging: A Guide for Patients and Non-Specialist Clinicians
Imaging — especially chest X-ray and high-resolution CT (HRCT) — is one of the most important tools for recognising, diagnosing and monitoring aspergillosis. Because the condition can affect the lungs in very different ways, seeing what is happening inside the chest is essential for both patients and clinicians.
This guide explains why imaging matters, how it is used, and provides links to trusted resources that show what aspergillosis looks like on scans.
Why Imaging Matters in Aspergillosis
Aspergillosis affects the lungs deep within the airway and lung tissue. Many of these changes cannot be detected by a stethoscope or blood tests alone. Imaging helps detect:
-
mucus plugging
-
bronchiectasis (damaged widened airways)
-
cavities (holes) in the lungs
-
fungal balls (aspergillomas)
-
inflammation and consolidation
-
scarring or fibrosis
-
signs of haemoptysis risk
In Allergic Bronchopulmonary Aspergillosis (ABPA), imaging may show mucus impaction or central bronchiectasis.
In Chronic Pulmonary Aspergillosis (CPA), it may show cavities, thickened cavity walls, or a fungus ball.
In invasive aspergillosis, imaging can detect early nodules, the “halo sign”, or rapidly progressing changes.
Understanding these patterns helps clinicians choose the right treatment at the right time, and helps patients make sense of what is happening in their lungs.
Key Online Resources for Aspergillosis Imaging
Radiopaedia – Open Radiology Reference
One of the clearest, most comprehensive imaging resources available.
-
Pulmonary aspergillosis overview:
https://radiopaedia.org/articles/pulmonary-aspergillosis?lang=gb -
Invasive pulmonary aspergillosis:
https://radiopaedia.org/articles/invasive-pulmonary-aspergillosis?lang=gb -
Aspergilloma (fungal ball):
https://radiopaedia.org/articles/aspergilloma?lang=gb
Why it’s useful:
Radiopaedia shows real CT and X-ray examples from multiple patients, helping you understand what radiologists look for and how different forms of aspergillosis appear on imaging.
Peer-Reviewed Pictorial Reviews
These academic reviews provide side-by-side CT examples of the full spectrum of disease, written in an accessible style and extremely useful for both patients and clinicians.
-
Imaging Spectrum in Chronic Pulmonary Aspergillosis (Garg et al., 2022)
https://pmc.ncbi.nlm.nih.gov/articles/PMC9833062/ -
Pictorial Essay: Forms of Pulmonary Aspergillosis (Tamkevičiūtė et al., 2024)
(abstract) https://www.ejradiology.com/article/S0720-048X%2824%2900006-8/abstract
These explain in pictures:
-
how cavities form
-
how aspergillomas look
-
early vs late changes
-
how ABPA patterns differ from CPA
-
what stable vs progressive disease looks like
They are especially helpful for GPs, respiratory trainees, and nurses learning to interpret fungal disease imaging.
Classic RSNA Radiographics Review (Franquet et al.)
A foundational article describing radiologic patterns in allergic, chronic and invasive aspergillosis.
Although technical, this remains a reference standard for understanding how fungal disease presents on CT.
National Aspergillosis Centre (UK) – Patient-Friendly Information
Clear explanations of why imaging is needed, how CT is used, and what typical findings mean.
-
Chronic Pulmonary Aspergillosis (CPA):
https://mft.nhs.uk/wythenshawe/services/infectious-diseases/national-aspergillosis-centre/about-aspergillosis/chronic-pulmonary-aspergillosis-cpa/
These pages are ideal for newly diagnosed patients, people preparing for CT scans, and clinicians who want a quick overview.
Asthma + Lung UK – General Aspergillosis Overview
Patient-friendly explanations of the different types of aspergillosis, diagnosis and treatment.
Includes mention of imaging when relevant.
How Imaging Guides Clinical Decisions
1. Confirming the Diagnosis
Different forms of aspergillosis look different on scans:
-
ABPA may show “finger-in-glove” mucus plugging or central bronchiectasis.
-
CPA requires a cavity seen on imaging for >3 months.
-
Aspergilloma is a fungal ball sitting within a cavity.
-
Invasive disease shows nodules, halo signs, or rapidly evolving infiltrates.
Without CT imaging, these distinctions cannot reliably be made.
2. Checking for Complications
Imaging detects:
-
new cavities
-
cavity wall thickening
-
risk of haemoptysis (bleeding)
-
pleural thickening
-
fibrosis
-
co-existing infections
These findings often trigger urgent or proactive treatment modifications.
3. Monitoring Progression and Treatment Response
Symptoms alone are not enough. Imaging shows whether:
-
disease is stable or progressing
-
antifungal treatment is working
-
inflammation is reducing
-
mucus plugging is clearing
-
new areas are becoming involved
This is why people with CPA or ABPA may have repeat CT scans, usually every 6–12 months or when symptoms worsen.
Using These Resources Safely
These resources are not for self-diagnosis. Instead, they help:
-
patients understand their own scan reports
-
GPs recognise when to refer to a specialist
-
hospital teams spot aspergillosis in complex or unclear cases
-
nurses and allied health professionals visualise lung changes
-
clinicians communicate findings more clearly
Imaging must always be interpreted by a trained radiologist or specialist team, but these materials help demystify the process.
Summary
Imaging is central to the diagnosis and management of aspergillosis. Whether you are a patient trying to understand your scans, a GP seeing a complex chest X-ray, or a hospital clinician assessing breathlessness, these imaging resources provide clear, trustworthy examples.
By learning what different patterns look like — mucus plugging, cavities, aspergillomas, fibrosis or invasive changes — non-specialists can make more confident decisions, and patients can better understand their condition.
The Chief Medical Officer’s Annual Report 2025: Infections
What this document is
The Chief Medical Officer’s Annual Report 2025: Infections is a major national review produced by the Chief Medical Officer for England, Professor Chris Whitty. It is a comprehensive, 371-page assessment of:
-
Current infectious disease threats in England
-
How infections are changing (ageing population, travel, globalisation, antimicrobial resistance)
-
What the NHS, public health services, and government need to do to protect the public
-
Key topics including vaccines, fungal infections, infection in older adults, housing, climate change and more
It includes contributions from national experts—including a full chapter dedicated to fungal infections (section 4.2) and others that touch on issues highly relevant to aspergillosis patients (vaccination, antimicrobial resistance, respiratory infections, housing, and vulnerable populations)
cmo-annual-report-2025-infectio…
Why it is published
The report is published each year to:
1. Advise Government
It sets out the CMO’s expert recommendations on how England should prepare for current and future infection threats, including pandemics, AMR, and emerging fungal pathogens.
2. Influence NHS planning and investment
The report highlights weaknesses in the system and proposes reforms.
This year’s report strongly emphasises:
-
Better infection services
-
Stronger surveillance
-
Improving vaccine uptake
-
Protecting older adults (now the group with most infection-related deaths)
-
Expanding superspecialist expertise—including fungal disease expertise
3. Inform clinicians, researchers, and public health professionals
It provides a current consensus on infectious disease trends, evidence, and priorities.
Chapters are written by leading UK experts in each field (e.g., fungal infections, antimicrobial resistance, vaccines, imported infections)
4. Educate the public and third-sector organisations
The report is open-access and intended to help the public understand why infection preparedness matters and why actions like vaccination, stewardship, and early diagnosis are essential.
Who reads it
The report is widely used across:
Government
-
Department of Health and Social Care
-
UKHSA
-
Cabinet Office (emergency planning)
-
Local authorities
NHS and clinical services
-
Infectious disease physicians
-
Respiratory teams
-
Microbiology and virology specialists
-
Primary care networks
-
ICS / ICB teams planning local services
Researchers and academic institutions
It sets the direction for future research and funding priorities, including for fungal disease and AMR.
Charities, patient organisations and advocates
Groups representing people with chronic, infectious, or respiratory illness read the report to understand system-level changes and advocate for patient needs.
Industry and diagnostics developers
They monitor future needs for antifungals, vaccines, and diagnostic tools.
Why this report is important for aspergillosis patients
Several aspects of the 2025 report directly relate to people with ABPA, CPA, SAFS or Aspergillus bronchitis.
1. Fungal infections are recognised as a major emerging threat
The report includes a dedicated chapter on fungal infections (section 4.2), describing:
-
Rising antifungal resistance
-
Expanding fungal threats globally
-
The importance of specialist mycology expertise
-
The risks from agricultural fungicides
-
The need for improved surveillance and diagnostics
This formal recognition strengthens the case for specialised centres like the National Aspergillosis Centre.
2. It highlights the need for superspecialists in rare and imported infections—including fungal disease
The CMO states that England requires:
“superspecialists to provide advice on and management of infections including… rarer [infections] such as fungal infections.”
cmo-annual-report-2025-infectio…
This directly supports the role and expansion of the NHS mycology services, which Aspergillus patients rely on for accurate diagnosis and treatment.
**3. It reinforces the importance of antimicrobial and antifungal stewardship
For people with aspergillosis, this matters because:
-
Resistance to azoles is rising—and the report explicitly mentions agricultural fungicides as part of the problem.
-
Stewardship ensures patients receive appropriate antifungals, monitored carefully and adjusted safely.
-
It argues for more drug development, which is essential because current antifungal options are limited.
4. It emphasises diagnosing infection in older adults
Older adults are increasingly vulnerable to infections and complications, especially respiratory ones.
The report stresses that:
-
Infection in older adults often has more serious consequences
-
Early diagnosis is essential
-
Access to specialist care must improve
Since many aspergillosis patients are older with complex lung disease, this section validates the need for better recognition and earlier referral.
5. Housing and damp are recognised as infection risks
The chapter Housing and Infection (section 7.2) discusses how substandard housing—including damp and mould—drives respiratory illness.
Although not Aspergillus-specific, it gives important public health backing for patients needing remediation and better housing conditions.
6. The report strengthens the case for national fungal surveillance
Key recommendations include:
-
Improving surveillance of antimicrobial and antifungal resistance
-
Better mapping of emerging pathogens
-
More research into fungal diseases
These system-level improvements directly benefit aspergillosis patients by helping earlier detection and better treatment options.
7. It raises awareness of fungal disease at national level
Simply being included in a flagship CMO report is important.
It means:
-
Policymakers can no longer overlook fungal infections
-
Funding for mycology services becomes easier to justify
-
Clinicians across the NHS will become more aware of CPA, ABPA and related diseases
-
It helps reduce the years-long diagnostic delays many patients face
In short — why Aspergillus patients should care
The 2025 CMO Annual Report is one of the most influential documents shaping future infectious disease strategy in England. For aspergillosis patients, it is important because:
✓ Fungal infections are explicitly highlighted as a growing threat
✓ Specialist mycology services are recognised as essential
✓ Antifungal resistance is identified as a major risk requiring action
✓ Better diagnosis and monitoring of at-risk groups is encouraged
✓ Housing, climate, age and vulnerability—all major issues for patients—are addressed
✓ It strengthens the case for investment in NAC and wider mycology networks
This report can be used by patient groups, NAC advocates, and healthcare professionals to press for:
-
More referrals
-
Better awareness among GPs and respiratory teams
-
Expanded mycology diagnostic capacity
-
Greater research funding
-
Better antifungal stewardship
-
National fungal surveillance
🌍 THE MICROBIOME REVOLUTION
How gut and lung microbiota are transforming the way we diagnose, treat and understand infection in aspergillosis


For decades, infection was seen through a simple lens:
Find the organism → treat the organism → infection cured.
But modern microbiome research has shown that this view is too narrow—especially for chronic lung diseases such as aspergillosis, bronchiectasis, ABPA, SAFS and CPA.
We now understand that the:
-
lungs,
-
gut,
-
sinuses,
-
skin, and even
-
CPA cavities
contain complex microbial ecosystems (bacteria, fungi, viruses, archaea) that interact dynamically with each other and with your immune system.
Rather than being passive passengers, these microbes shape inflammation, immunity, symptoms, resistance, treatment response and overall wellbeing.
This is why microbiome science is truly revolutionising how clinicians think about infection.
🧬 1. What is a microbiome?
A microbiome is the entire community of microorganisms living in a particular environment, plus all the genes, chemicals, signals and interactions that exist between them.
Healthy microbiomes are:
-
diverse
-
stable
-
environmentally balanced
-
dominated by harmless or beneficial species
Disease-associated microbiomes are:
-
less diverse
-
unstable
-
dominated by a few harmful organisms
-
deeply involved in inflammation
This imbalance is called dysbiosis.
🫁 2. The lung microbiome: complex, dynamic, and vital
The lungs are not sterile—they contain a delicate, low-density microbiome.
In health, microbes drift in and out through:
-
breathing
-
micro-aspiration
-
mucociliary clearance
The “healthy lung microbiota” remains balanced because airflow and immune regulation prevent any single species from dominating.
In disease (aspergillosis, bronchiectasis, ABPA, SAFS, CPA), the situation changes:
-
thick mucus traps microbes
-
reduced airflow produces stagnant zones
-
inflammation increases microbial stickiness
-
biofilms form
-
pathogens dominate
-
microbial diversity drops
-
chronic inflammation becomes self-sustaining
This drives persistent symptoms even when cultures appear negative.
🍽️ 3. The gut microbiome: our “second immune system”


The gut contains trillions of bacteria, fungi and viruses.
Far from being limited to digestion, the gut microbiome influences:
-
immune development
-
inflammation control
-
IgE responses
-
eosinophils
-
energy levels
-
weight regulation
-
steroid responsiveness
-
susceptibility to infection
-
mental wellbeing
Up to 70% of your immune system is shaped by gut microbes.
This means:
Gut health directly affects lung health, including risk and severity of aspergillosis-related disease.
🔄 4. The Gut–Lung Axis: how the two microbiomes talk to each other
The gut and lungs are connected through a biochemical “highway” known as the gut–lung axis.
How the gut affects the lungs
Gut bacteria produce metabolites such as:
-
short-chain fatty acids (SCFAs) — e.g., butyrate
-
tryptophan metabolites
-
bile-acid derivatives
These travel in the bloodstream and regulate:
-
airway inflammation
-
Th2/Th17 immune responses
-
IgE and eosinophils
-
neutrophil activity
-
mucus production
-
tolerance to allergens (including fungal allergens)
-
steroid responsiveness
Low SCFA levels are linked to:
-
more severe asthma
-
worse fungal sensitisation
-
increased ABPA flares
-
poorer lung function
-
difficulty clearing infection
How lung disease affects the gut
Chronic respiratory disease increases:
-
gut permeability (“leaky gut”)
-
microbiota disruption
-
systemic inflammation
-
digestive symptoms
-
fatigue
-
candida overgrowth
Steroids and antibiotics worsen this further.
This creates a self-reinforcing circle of inflammation and dysbiosis.
🧱 5. Biofilms: microbial fortresses driving persistent disease
Biofilms are communities of microbes encased in a sticky protective matrix.
In aspergillosis and bronchiectasis, biofilms:
-
make organisms up to 100–1000× more resistant to treatment
-
protect microbes from the immune system
-
allow bacteria and fungi to communicate and collaborate
-
swap resistance genes
-
support mixed infections (e.g., Aspergillus + Pseudomonas)
-
cause chronic symptoms even with “negative” cultures
Biofilms also change the immune system’s behaviour, driving long-term inflammation.
🔬 6. What microbiome research has revealed so far
A. Infection is rarely a single organism
Microbiomes show that infections are polymicrobial ecosystems, not isolated pathogens.
B. Diversity = resilience
Higher microbial diversity is linked to:
-
better lung stability
-
fewer flare-ups
-
lower inflammation
Low diversity correlates with:
-
severe disease
-
CPA progression
-
ABPA flares
-
worse bronchiectasis outcomes
C. Microbiome patterns can predict future illness
Research shows that flare-ups often follow:
-
a drop in diversity
-
an increase in dominant pathogens
-
changes in fungal–bacterial interactions
D. Treatment responses are microbiome-dependent
The presence of certain bacteria can make Aspergillus:
-
grow faster
-
form stronger biofilms
-
resist antifungals
-
provoke more inflammation
🫁🌱 7. What patients can do to support their lung microbiota
Just as dietary fibre supports gut microbes, there are practical steps that support a healthier lung microbial ecosystem.
These steps do not introduce microbes into the lungs; instead, they improve the environment the microbiota lives in.
⭐ 1. Keep airways clear — the foundation of lung microbial health
Biofilms and harmful microbes thrive in stagnant mucus.
Effective clearance techniques:
-
Active Cycle of Breathing Techniques (ACBT)
-
Autogenic drainage
-
Oscillating devices (Flutter, Acapella, Aerobika)
-
Nebulised saline (3–7%)
-
Huffing and controlled coughing
Clearer airways → more airflow → better microbial balance.
⭐ 2. Hydration
Hydration thins mucus, improves ciliary function, and weakens biofilms.
⭐ 3. Use inhalers correctly & control inflammation
Inflamed, narrowed airways promote dysbiosis.
Good control of:
-
asthma
-
ABPA
-
eosinophilia
reduces microbial imbalance.
⭐ 4. Improve sinus health
The sinuses drip microbes into the lungs all day long.
Sinus care (saline rinses, nasal steroids) supports lung microbiota stability.
⭐ 5. Avoid unnecessary antibiotics
Antibiotics disrupt:
-
lung microbiota
-
gut microbiota
-
fungal–bacterial balance
-
biofilm behaviour
Use them when needed — but avoid repeated unnecessary courses.
⭐ 6. Exercise
Exercise increases airflow and clearance, helping shift the lung microbiome toward a healthier, more diverse state.
⭐ 7. Reduce smoke and indoor pollutants
Pollutants:
-
paralyse cilia
-
thicken mucus
-
promote pathogenic microbes
-
reduce diversity
HEPA filtration, ventilation, and smoke avoidance all help.
⭐ 8. Manage reflux (GORD)
Micro-aspiration introduces stomach contents into the lungs, disrupting the lung microbiota.
Treating reflux supports lung microbial homeostasis.
⭐ 9. Support your gut microbiota
A healthy gut → more SCFAs → improved lung immunity → a more balanced lung microbiome.
Helpful for gut health:
-
fibre-rich foods
-
diverse diet
-
fermented foods (if tolerated)
-
avoiding unnecessary antibiotics
-
reducing alcohol
-
managing stress
🩺 8. What this means for the future of aspergillosis care
Within 5–10 years, we may routinely use:
-
microbiome sequencing in clinic
-
AI-designed “ecosystem maps” of the lungs
-
targeted therapies for mixed infections
-
inhaled agents that break down biofilms
-
gut-directed therapies to help lung disease
-
personalised airway clearance plans
-
microbial diversity scores to predict flares
This could:
-
reduce exacerbations
-
minimise antibiotic and antifungal exposure
-
improve quality of life
-
slow CPA progression
-
improve steroid responsiveness
-
reduce hospital admissions
🧠 9. Key takeaways
-
You have two important microbiomes that matter for aspergillosis:
the lung microbiome and the gut microbiome. -
They communicate through the gut–lung axis.
-
Dysbiosis (imbalance) increases inflammation and worsens fungal disease.
-
Biofilms make infections far more resistant and persistent.
-
Patients can support their lung microbiota through lifestyle steps, especially:
-
airway clearance
-
hydration
-
exercise
-
sinus care
-
avoiding unnecessary antibiotics
-
supporting gut health
-
-
Microbiome science is transforming future diagnosis and treatment strategies.
Verified UK Resources for Damp, Mould & Health
Here is a short, reliable, UK-verified list of resources for people worried about damp, mould and health. Each link is trustworthy, evidence-based, and not influenced by companies selling testing or “mycotoxin cleanses”.
1. NICE – Damp and Mould Guidelines
This guideline covers indoor air quality in residential buildings. It aims to raise awareness of the importance of good air quality in people's homes and how to achieve this.
🔗 https://www.nice.org.uk/guidance/NG149
2. UK Health Security Agency (UKHSA) – Damp & Mould Health Guidance
The most authoritative public health guidance used by councils, housing providers, and clinicians.
Includes:
-
How mould affects health
-
Who is at higher risk
3. Shelter – Tenant Rights on Damp and Mould
For renters needing practical, legal steps to get repairs done.
🔗Damp and mould in private rented homes
🔗Damp and mould in council and housing association homes
4. Citizens Advice – Step-by-Step Action for Damp Problems
Simple language, includes letter templates for landlords.
🔗 https://www.citizensadvice.org.uk/housing/repairs-and-housing/repairs-and-housing-conditions/whos-responsible-for-repairs/repairs-damp/
5. Housing Ombudsman – Damp & Mould Guidance for Social Housing
Very helpful for council and housing association tenants dealing with delays or poor responses.
🔗 https://www.housing-ombudsman.org.uk/damp-and-mould/
6. Awaab’s Law Information (Housing Ombudsman)
Sets strict deadlines for social landlords to investigate and fix reported damp/mould.
🔗 https://www.housing-ombudsman.org.uk/centre-for-learning/key-topics/awaabs-law/
7. Asthma + Lung UK – Mould and Breathing Problems
Good for people with asthma, COPD, ABPA or bronchiectasis.
Practical tips and when to seek medical help.
🔗 https://www.asthmaandlung.org.uk/blog/advice-support/know-your-rights-what-do-if-you-have-damp-mould-rented-home
8. London Fire Brigade – Safe Use of Dehumidifiers & Ventilation Advice
Useful because many people misuse heaters or dehumidifiers while trying to “dry out” a home.
🔗https://www.london-fire.gov.uk/safety/
9. Royal Institution of Chartered Surveyors
The Royal Institution of Chartered Surveyors (RICS) is the global professional body setting standards for land, property, construction and the built environment. Its members help ensure that buildings and infrastructure are safe, well-managed and sustainable, providing trusted expertise for governments, industry and the public.
https://www.rics.org/consumer-guides/damp-and-mould
Optional extras (carefully chosen):
World Health Organization – Indoor Dampness & Health Review
A global evidence assessment → helps debunk myths about “toxic mould” testing.
🔗 https://www.who.int/publications/i/item/9789289041683
Important reassurance you can give people
These sources are aligned on three key points:
✔ Mould exposure can worsen asthma, allergies and respiratory illness.
Especially in children, older adults, and people with chronic lung conditions (like ABPA, CPA, bronchiectasis).
✔ Mycotoxins in UK homes are not a common cause of chronic, systemic illness.
Reputable agencies (NHS, UKHSA, WHO) do not support “mycotoxin testing” or expensive “detox” treatments.
✔ Fixing the building is the most important treatment.
Ventilation, reducing humidity, removing contaminated soft furnishings, and remediation are the real interventions.
Aspergillosis Research Highlights — Week in Review (Last 7 Days: Week 50)
Seven key publications: pathogenicity, diagnostics, resistance, treatment, maxillofacial disease, and ABPA in COPD.
1. Comparative Overview of A. fumigatus, A. flavus, and A. niger
Rafique et al., J Infect Public Health, 2025
DOI: 10.1016/j.jiph.2025.103070
What this adds
-
A major comparative review (2000–2025) of the three most clinically relevant Aspergillus species.
-
Highlights broad clinical spectrum: allergy → chronic disease → invasive aspergillosis.
-
Identifies species-specific concerns:
-
A. fumigatus: globally dominant, rapidly evolving triazole resistance.
-
A. flavus: important in warmer climates; high aflatoxin relevance.
-
A. niger: relatively lower virulence but significant in sinus disease.
-
-
Public health message: surveillance gaps persist, especially for non-fumigatus species.
Why it matters
A strong reference paper supporting the WHO prioritisation of Aspergillus, and reinforcing the need for:
-
Better diagnostics
-
Species-level identification
-
Environmental resistance monitoring
2. GFP Fusion Protein Proteolysis in A. fumigatus
Paul & Moye-Rowley, G3 (Bethesda), 2025
DOI: 10.1093/g3journal/jkaf295
What this adds
-
Fundamental molecular biology study revealing regulated degradation pathways of green fluorescent protein (GFP) fusion proteins inside A. fumigatus.
-
Demonstrates how the fungus controls protein turnover under stress conditions.
Why it matters
-
Advances tools for fungal cell biology.
-
Supports drug development by clarifying pathways involved in stress response and antifungal tolerance.
-
Reinforces WHO’s classification of A. fumigatus as one of the four most critical fungi to study.
3. ABPA in COPD: Case Series + Review
Ren et al., BMC Pulmonary Medicine, 2025
DOI: 10.1186/s12890-025-04027-8
What this adds
-
11 COPD cases with confirmed Allergic Bronchopulmonary Aspergillosis — highlighting:
-
Under-recognition in COPD
-
Overlap with chronic bronchitis/bronchiectasis symptoms
-
Frequent misdiagnosis as recurrent infections or COPD exacerbations
-
-
Provides diagnostic guidance and a literature synthesis.
Why it matters
-
Significant implications for case finding across the UK.
-
Supports NAC messaging: ABPA is not only an asthma disease.
-
Reinforces need for:
-
IgE/IgG screening
-
Early CT imaging
-
Awareness among COPD teams and primary care
-
4. EL219: Next-Generation Polyene Antifungal
Youssef et al., AAC, 2025
DOI: 10.1128/aac.01400-25
What this adds
-
Animal model evidence that EL219, a modern polyene, is effective against:
-
Triazole-susceptible A. fumigatus
-
Azole-resistant isolates
-
Difficult species (A. lentulus, A. calidoustus)
-
Why it matters
-
Highly relevant to rising global antifungal resistance.
-
Early indication that EL219 may fill a clinical gap similar to (or complementary to) olorofim and fosmanogepix.
-
Suggests strong activity even in immunosuppressed models.
5. Misidentification & Triazole Resistance in Aspergillus tubingensis
Wang et al., JAMA Network Open, 2025
DOI: 10.1001/jamanetworkopen.2025.43630
What this adds
-
Large Southern California population study showing:
-
Frequent misidentification of A. tubingensis as A. niger.
-
Notable azole resistance rates in correctly identified isolates.
-
-
Stresses need for genomic sequencing or MALDI-TOF with updated libraries.
Why it matters
-
Strong evidence that misidentification leads to:
-
Inappropriate antifungal therapy
-
Poor outcomes
-
-
Supports calls for expanded diagnostic reference services such as MRCM.
6. 50-Year Review of Oral Fungal Infections in Thailand
Kosanwat et al., Clinical Oral Investigations, 2025
DOI: 10.1007/s00784-025-06685-8
What this adds
-
Longitudinal study: 29% of deep infections involved aspergillosis.
-
Mean age 62 → older adults most affected.
-
Many cases were mucormycosis, histoplasmosis, or aspergillosis presenting late.
Why it matters
-
Shows that oral/maxillofacial fungal disease remains under-recognised globally.
-
Relevant to dental teams → better imaging + biopsy protocols needed.
-
May help NAC/CARES identify referral pathways from dental medicine.
7. Management of Maxillary Sinus Aspergillosis with Implants
Khoury et al., Int J Oral Implantol, 2025
What this adds
-
Real-world 3–10 year follow-up of 11 patients.
-
Standardised approach:
-
Surgical clearance
-
Antifungal therapy
-
Successful implant-prosthetic rehabilitation
-
Why it matters
-
Demonstrates excellent long-term outcomes when sinus aspergillosis is properly treated.
-
Practical implications for:
-
ENT surgeons
-
Oral surgeons
-
Implant dentistry
-
-
Supports inclusion of aspergillosis in sinus disease differential diagnosis.
Cross-Cutting Themes Emerging This Week
1. Under-recognition and misidentification
-
ABPA in COPD
-
Misidentified A. tubingensis
-
Asymptomatic sinus disease
-
Oral/maxillofacial deep fungal infections
→ Key NAC message: We are missing cases in primary care, COPD clinics, ENT, and dentistry.
2. Antifungal resistance remains a central threat
-
Contemporary reviews of species-specific resistance patterns
-
EL219’s promise against resistant species
-
Misidentification leading to incorrect susceptibility assumptions
3. Need for better diagnostics and reference centres
-
Species-level identification is essential
-
Supports arguments for expansion of MRCM-style national services
4. The clinical spectrum is broad
From allergy (ABPA in COPD) → chronic sinus disease → deep oral infections → invasive pulmonary aspergillosis.
This reinforces the message: aspergillosis is multi-specialty, not confined to respiratory medicine.
Weekly NAC/MRCM Take-Home Messages
-
COPD teams should screen for ABPA more frequently—especially in patients with recurrent “infective exacerbations.”
-
Species-level identification is increasingly important; misidentification contributes to treatment failure.
-
New antifungals like EL219 show promise against resistant strains including A. lentulus.
-
Dental and ENT teams need better awareness: sinus and oral fungal infections remain overlooked but treatable.
-
Global reviews show growing public health significance of Aspergillus species—aligning with WHO priorities.










